Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease
1 other identifier
observational
73
1 country
1
Brief Summary
Serum NGAL has been described as a biomarker of neutrophil activation and an inflammatory marker which correlates to obesity and its metabolic complications. Since neutrophil activation has been implicated in the pathogenesis of coronary artery disease, the investigators hypothesized that serum NGAL levels would be higher in patients with CAD and that serum concentration would correlate with the extent of CAD as documented by coronary angiography, serving as a potential biomarker of the severity of CAD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2008
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2008
CompletedFirst Submitted
Initial submission to the registry
September 8, 2008
CompletedFirst Posted
Study publicly available on registry
September 9, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2009
CompletedJuly 8, 2010
August 1, 2009
6 months
September 8, 2008
July 7, 2010
Conditions
Keywords
Study Arms (2)
1
Patients with angiographically confirmed significant CAD
2
Patients without significant CAD
Eligibility Criteria
Patients admitted for coronary angiography.
You may qualify if:
- Consenting patients undergoing coronary angiography due to suspected CAD based on clinical history and results from non-invasive testing
You may not qualify if:
- Abnormal renal function
- Any known active inflammatory disease
- Receiving medical therapy with antibiotics, corticosteroids, immunosuppressive agents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Athens Euroclinic
Athens, Attica, 11521, Greece
Biospecimen
Serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Demosthenes Katritsis, MD,PhD
Athens Euroclinic and Cardiovascular Research Society
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 8, 2008
First Posted
September 9, 2008
Study Start
September 1, 2008
Primary Completion
March 1, 2009
Study Completion
September 1, 2009
Last Updated
July 8, 2010
Record last verified: 2009-08